Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Maridebart Cafraglutide on Oral Contraceptive PK in Postmenopausal Women With Overweight/Obesity
NCT07523711Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of maridebart cafraglutide in obesity, sponsored by Amgen. Primary endpoints: Maximum Observed Concentration of COC, Area Under the Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration of COC and 1 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07523711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523711.